Skip to main content
SpringerLink
Log in

The Immunotherapy of Bladder Cancer

  • Chapter
Book cover Immunology for Surgeons

  • 142 Accesses

Abstract

Bladder Cancer is the fifth most common cancer in the Western World, with a projected estimate of 55,000 new cases in 2001 in the United States. It accounts for about 6.3 percent of all new cases of cancer amongst men, with the lifetime risk of being diagnosed with bladder cancer around 3.5 percent. In the United Kingdom, bladder cancer is the second most common urological malignancy, with an estimated 13,000 new cases and 5,500 deaths from this disease occurring each year [1].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Silverman DT, Rothman N, Devesa SS. Epidemiology of bladder cancer. In: Syrigos KN, Skinner DG, editors. Bladder cancer: biology, diagnosis and management. London: Oxford University Press, 1999;11–55.

    Google Scholar 

  2. Hall D, Battin J, Nseyo UO, Lamm DL. Immunotherapy of bladder cancer. In: Syrigos KN, Skinner DG, editors. Bladder cancer: biology, diagnosis and management. London: Oxford University Press, 1999;345–58.

    Google Scholar 

  3. Morales A, Eidenger D, Bruce AW. Intracavitary bacillus Calmette-Guerin in the treatment of superficial tumors. J Urol 1976;116:127.

    Google Scholar 

  4. Patard JJ, Saint F, Velotti F, et al. Immune response following intravesical bacillus Calmette-Guerin instillations in superficial bladder cancer: A review. Urol Res 1998;26:155.

    Article  CAS  PubMed  Google Scholar 

  5. Herr HW. Carcinoma in situ of the bladder. Semin Urol 1983;1:15.

    CAS  PubMed  Google Scholar 

  6. Lamm DL. Carcinoma in situ. Urol Clin North Am 1992;19:573.

    CAS  PubMed  Google Scholar 

  7. Lamm DL, Crawford ED, Blumenstein B. SWOG 8795: A randomized comparison of BCG and mitomycin C prophylaxis in stage Ta and T1 transitional cell carcinoma of the bladder. J Urol 1993;149:275.

    Google Scholar 

  8. Heney NM, Ahmed S, Flanagan MJ, et al, for the National Bladder Cancer Collaborative Group A (NBCCGA). Superficial bladder cancer: Progression and recurrence. J Urol 1983;130:1083.

    CAS  PubMed  Google Scholar 

  9. Pagano F, Garbeglio A, Milani C, et al. Prognosis of bladder cancer. I. Risk factors in superficial transitional cell carcinoma. Eur Urol 1987;13:145.

    CAS  PubMed  Google Scholar 

  10. Jakse G, Loidl W, Seeber G, et al. Stage T1, grade 3 transitional cell carcinoma of the bladder: An unfavorable tumor? J Urol 1987;137:39.

    CAS  PubMed  Google Scholar 

  11. Dalbagni G, Herr HW. Current use and questions concerning intravesical bladder cancer group for superficial bladder cancer.

    Google Scholar 

  12. Koukol SC, DeHaven JL, Riggs DR, Lamm DL. Drug therapy of BCG sepsis. Urol Res 1995;22:373.

    Article  CAS  PubMed  Google Scholar 

  13. Kritstjansson M, Green P, Manning HL. Molecular confirmation of BCG as the cause of pulmonary infection following urinary tract instillation. Clin Infect Dis 1993;17:228.

    Article  Google Scholar 

  14. Lamm DL, De Haven JI, Riggs DR, et al. Immunotherapy of murine bladder cancer with keyholelimpet hemocyanin (KLH). J Urol 1993;149:648.

    CAS  PubMed  Google Scholar 

  15. Lamm DL, Haven JL, Riggs DR. KLH immunotherapy of murine bladder cancer. Urol Res 1993;21:7.

    Article  Google Scholar 

  16. Lamm DL, Morales A, Grossman HB. KLH immunotherapy of papillary and in situ transitional cell carcinoma of the bladder. A multicenter phase I–II clinical trial. J Urol 1996;155:1405A.

    Google Scholar 

  17. Jurinicic CD, Englemann U, Gasch J, et al. Immunotherapy in bladder cancer with keyhole-limpet hemocyanin: A randomized study. J Urol 1988;139:723.

    Google Scholar 

  18. Lotzova E, Savary CA, Stringfellow DA. Pyrimidones: new molecules with cancer therapeutic potential and interferon-inducing capacity are strong inducers of murine natural killer cells. J Immunol 1983;130:965.

    CAS  PubMed  Google Scholar 

  19. Sarosdy MF, Lowe BA, Schellhammer PF. Bropirimine immunotherapy of bladder CIS. Phase II results of an oral interferon inducer. Proc Annu Meeting ASCO 1994;13:719A.

    Google Scholar 

  20. Sarosdy MF, Lowe BA, Schellhammer PF. Oral bropirimine immunotherapy of carcinoma in situ of the bladder: results of a phase II trial. Urology 1996;48:21.

    Article  CAS  PubMed  Google Scholar 

  21. Kostakopoulos A, Deliveliotis C, Mavromanolakis E, et al. Intravesical interferon alpha-2b administration in the treatment of superficial bladder tumors. Eur Urol 1990;18:201A.

    Google Scholar 

  22. Bartoletti R, Massimini G, Criscuolo D, et al. Interferon alpha 2a in superficial bladder cancer prophylaxis: Toleration and long-term follow-up. A phase I–II study. Anticancer Res 1991;11:2167A.

    Google Scholar 

  23. Portillo J, Martin B, Hernandez R, et al. Results at 43 months’ follow up of a double-blind, randomized, prospective clinical trial using intravesical interferon alpha-2b in the prophylaxis of stage pT1 transitional cell carcinoma of the bladder. Urology 1997;49:187.

    Article  CAS  PubMed  Google Scholar 

  24. Giannakopoulos S, Gekas A, Alivizatos G, et al. Efficacy of escalating doses of intravesical interferon alpha-2b in reducing recurrence rate and progression in superficial transitional cell carcinoma. Br J Urol 1998;82:829.

    Article  CAS  PubMed  Google Scholar 

  25. Oliver RTD, Waxman JH, Kwok H, et al. Alpha lymphoblastoid interferon for noninvasive bladder cancer. Br J Cancer 1986;53:432.

    Google Scholar 

  26. DiStasi SM, Vergilli G, Vespasiani G, et al. Intralesional alpha interferon therapy in papillary superficial transitional cell carcinoma of the bladder: A pilot study. Br J Urol 1993;71:422.

    Article  CAS  Google Scholar 

  27. Geboers ADH, van Bergen TNLM, Oosterlinck W. Gamma-interferon in the therapeutic and prophylactic management of superficial bladder cancer. J Urol 1987;137:276.

    Google Scholar 

  28. Migliari R, el Demiri M, Muscas G, et al. Intravesical installation of beta-interferon in the treatment of bladder cancer. Br J Urol 1992;70:169.

    Article  CAS  PubMed  Google Scholar 

  29. Niijima T. Intravesical treatment of bladder cancer with recombinant human interferon-beta: Intravesical GKT-beta chemotherapy research group. Cancer Immunol Immunother 1989;30:81.

    Article  CAS  PubMed  Google Scholar 

Download references

Authors
  1. Konstantinos N. Syrigos
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Anastasios J. Karayiannakis
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Kaplan Medical Center, PO Box 23273, King George PO Branch, 61231, Tel Aviv, Israel

    Andrew P. Zbar (Head of Colorectal Surgery,Senior Consultant Colorectal Surgeon) (Head of Colorectal Surgery,Senior Consultant Colorectal Surgeon)

  2. St James’s University Hospital, School of Medicine, Division of Surgery, University of Leeds, Clinical Sciences Building, Leeds, LS9 7TF, UK

    Pierre J. Guillou

  3. Department of Surgery, University of Alabama School of Medicine, Boshell Diabetes Building,1808 7th Avenue South, Birmingham, AL, 35233, USA

    Kirby I. Bland (Professor and Chairman Dept of Surgery) (Professor and Chairman Dept of Surgery)

  4. Oncology Unit 3rd Department Medicine, Athens Medical School Sotiria General Hospital, Athens, Greece

    Konstantinos N. Syrigos (Associate Professor of Medical Oncology, Head) (Associate Professor of Medical Oncology, Head)

Rights and permissions

Reprints and permissions

Copyright information

© 2002 Springer-Verlag London

About this chapter

Cite this chapter

Syrigos, K.N., Karayiannakis, A.J. (2002). The Immunotherapy of Bladder Cancer. In: Zbar, A.P., Guillou, P.J., Bland, K.I., Syrigos, K.N. (eds) Immunology for Surgeons. Springer, London. https://doi.org/10.1007/978-1-4471-0201-4_18

Download citation

  • DOI: https://doi.org/10.1007/978-1-4471-0201-4_18

  • Publisher Name: Springer, London

  • Print ISBN: 978-1-85233-482-6

  • Online ISBN: 978-1-4471-0201-4

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation